4th Targeted Protein Degradation Summit Europe - Market Insights
As the industry consolidates pipelines and heads out of a turbulent 2023 market, the targeted protein degradation engine has shown no signs of slowing. Our blossoming community of degrader experts are inspiring each other to develop medicines to address patients’ unmet medical needs. Dedicated to Progressing the Field with Groundbreaking Research.
Verified
Targeted Protein Degradation Europe 2022 Deep Proteomic Screening for Systematic Discovery of Novel Degrader Targets
High-throughput proteome-wide degrader characterization with unparalleled sensitivity, data completeness, and turnaround times Identification of novel degrader targets, monitoring of proteome-wide selectivity, and detection of molecules acting through new E3 ligases and emerging TPD mechanisms. Demonstration of degrader-induced modification by ubiquitinomics to a depth of up to 50.000 sites and detection of degrader-induced E3 ligase binding…Read more
Verified
Targeted Protein Degradation Europe 2022 GlueE3, A Modelling Platform for True Rational MG Screening
Modelling is capable of accurately pair ligases with proteins of interest (POI) Given a ligase-POI binary complex, glueE3 can rationally (and efficiently) screen for novel MGs Using Large Language Models we can learn the protein-protein dialect, revealing intriguing aspects of ligase pairingRead more
Verified
Targeted Protein Degradation Europe 2022 Discovery, Characterisation, & Optimisation of CBP Selective Degraders
Identifying and optimizing potent, selective degraders of CBP to address mutant EP300 Cancers Spotlighting demonstrated, robust activity in preclinical pk/pd and efficacy models Demonstrating no observed thrombocytopenia in mice at pharmacologically relevant dosesRead more
View all products
Keywords
Industries
Targeted Protein Degradation Europe 2022 Improving Pre-Clinical Safety Assessment with Microphysiological Systems
Outline the context of use of microphysiological systems (MPS) to generate safety and efficacy data for drug development with improved clinical relevance over more traditional 2D cell culture and animal models Highlight examples of data generated from these systems that demonstrate the utility of MPS for safety assessment Current challenges to the adoption and/or development…Read more
Where is 16250 - 1st TPD Europe 2020 located?
The company 16250 - 1st TPD Europe 2020 is located in London, England, United Kingdom. It's worth noting that the company may has more corporate locations
How many employees does 16250 - 1st TPD Europe 2020 approximately have?
As of the latest available information 16250 - 1st TPD Europe 2020 has around 1-10 employees worldwide.
In which industries does 16250 - 1st TPD Europe 2020 mainly work?
The company 16250 - 1st TPD Europe 2020 has it's main focus in the industries of Others
